AC Immune

AC Immune

Biotechnologieforschung

Lausanne, Vaud 15.627 Follower:innen

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention.

Info

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

Branche
Biotechnologieforschung
Größe
51–200 Beschäftigte
Hauptsitz
Lausanne, Vaud
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2003
Spezialgebiete
Therapeutics , Alzheimer's disease, Neuro-orphan diseases, Parkinson's disease, Diagnostics, Neurodegenerative diseases, Down syndrome und Misfolded proteins

Orte

Beschäftigte von AC Immune

Updates

Ähnliche Seiten

Finanzierung